diflunisal ( 500 mg orally , twice daily ) and naproxen ( 375 mg orally , twice daily ) were compared for efficacy and tolerability in a 12-week open-label study in 33 patients with active rheumatoid arthritis ( ra ) .
C0012228
diflunisal
C0003873
rheumatoid arthritis